Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Claim review
Peptide nootropic stack claims — review
The nootropic-stack space combines Russian-developed peptides (Semax, Selank), historical sleep peptides (DSIP), preclinical-only experimental compounds (Dihexa), and licensed-in-some-jurisdictions multi-peptide preparations (Cerebrolysin). Marketed as 'focused calm' or 'smart drug' alternatives. This page covers what the actual evidence supports.
Common nootropic-stack claims
- “Smart drug without the side effects”
- “Focused calm — stimulant cognition without anxiety”
- “Reverses brain ageing”
- “Treats long COVID brain fog”
The honest picture
Russian-jurisdiction clinical evidence exists for Semax (stroke recovery), Selank (anxiety), and Cerebrolysin (stroke / dementia). Western Phase 3 replication is limited. Healthy-adult cognitive-enhancement outcome trials largely do not exist.
The evidence-based UK cognitive pathway
- Regular aerobic exercise — the strongest single intervention for cognitive maintenance.
- Sleep adequacy, social engagement, novel skill learning.
- NHS Talking Therapies for mood / anxiety driving cognitive symptoms.
- GP referral for adult ADHD assessment if attention concerns are lifelong.
- NHS memory clinic for genuine cognitive decline.
Frequently asked questions
- Do peptide nootropic stacks improve cognition in healthy adults?
- No Western Phase 3 cognitive-enhancement trial supports any of these compounds for healthy-adult cognitive improvement. Russian-licensed clinical use is for specific neurological indications, not nootropic optimisation.
- What is the evidence picture for each compound?
- Semax / Selank — Russian licensed for stroke and anxiety, limited Western replication. DSIP — sparse historical sleep data. Dihexa — preclinical only, theoretical c-Met / oncologic concerns. Cerebrolysin — licensed in many jurisdictions for stroke / dementia, not MHRA-licensed.
- Are these legal in the UK?
- None are MHRA-licensed. Personal-use importation sits in regulatory grey area; sale with cognitive-enhancement claims engages UK medicines regulation.
- What about long-term safety?
- Long-term healthy-adult safety is essentially unstudied for any of these compounds. Combination safety is uncharacterised. Interactions with SSRIs, stimulants, and other CNS medicines are unknown.
- What is the evidence-based cognitive pathway?
- Sleep, exercise, social engagement, and learning new skills have the strongest evidence for cognitive maintenance. NHS Talking Therapies for mood-driven cognitive complaints. GP referral for memory or attention concerns that affect function — many treatable causes exist (sleep apnoea, depression, thyroid, B12, ADHD).